Proportion of Prescribed Conditions & Latest Patient Approval Numbers To date, the TGA has approved SAS applications including, but not limited to, the following indications: chemotherapy-induced nausea and vomiting refractory paediatric epilepsy palliative care indications cancer pain neuropathic pain spasticity from neurological conditions anorexia and wasting associated with chronic illness (such as cancer) A break […]
Read More
UK CBD Sales Surge Research from two industry pressure groups reveals the UK cannabinoid (CBD) industry was worth £690mln in the 12 months to the end of April – up almost a third since a 2019 estimate. CBD is the non-psychoactive element derived from both marijuana and hemp plants. It is used in an […]
Read More
Medical Cannabis: where are we at? This is a fantastic article by respected experts Associate Professor Vicki Kotsirilos AM was Australia’s first authorised GP prescriber of medicinal cannabis in May 2018. Professor Iain S McGregor is the Academic Director of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney’s Brain and Mind Centre. […]
Read More
To date, the TGA has approved SAS applications including, but not limited to, the following indications: chemotherapy-induced nausea and vomiting refractory paediatric epilepsy palliative care indications cancer pain neuropathic pain spasticity from neurological conditions anorexia and wasting associated with chronic illness (such as cancer). The above list is provided as an overview and does not […]
Read More
TGA allows OTC sales of Cannabidiol The medical cannabis industry took a big step forward in Australia today with the announcement from the regulator. The Therapeutic Goods Administration or TGA has announced it will down-schedule cannabidiol (CBD) in low dose preparations from Schedule 4 (defined as prescription medications) to Schedule 3 available in pharmacies. According […]
Read More